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Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder
worldwide affecting 2–3% of the population over 65 years. This prevalence is
expected to rise as life expectancy increases and diagnostic and therapeutic protocols
improve. PD encompasses a multitude of clinical, genetic, and molecular forms of
the disease. Even though the mechanistic of the events leading to neurodegeneration
remain largely unknown, some molecular hallmarks have been repeatedly reported
in most patients and models of the disease. Neuroinflammation, protein misfolding,
disrupted endoplasmic reticulum-mitochondria crosstalk, mitochondrial dysfunction
and consequent bioenergetic failure, oxidative stress and autophagy deregulation,
are amongst the most commonly described. Supporting these findings, numerous
familial forms of PD are caused by mutations in genes that are crucial for
mitochondrial and autophagy proper functioning. For instance, late and early onset PD
associated to mutations in Leucine-rich repeat kinase 2 (LRRK2) and Parkin (PRKN)
genes, responsible for the most frequent dominant and recessive inherited forms
of PD, respectively, have emerged as promising examples of disease due to their
established role in commanding bioenergetic and autophagic balance. Concomitantly,
the development of animal and cell models to investigate the etiology of the disease,
potential biomarkers and therapeutic approaches are being explored. One of the
emerging approaches in this context is the use of patient’s derived cells models, such as
skin-derived fibroblasts that preserve the genetic background and some environmental
cues of the patients. An increasing number of reports in these PD cell models postulate
that deficient mitochondrial function and impaired autophagic flux may be determinant
in PD accelerated nigral cell death in terms of limitation of cell energy supply and
accumulation of obsolete and/or unfolded proteins or dysfunctional organelles. The
reliance of neurons on mitochondrial oxidative metabolism and their post-mitotic nature,
may explain their increased vulnerability to undergo degeneration upon mitochondrial
challenges or autophagic insults. In this scenario, proper mitochondrial function and
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turnover through mitophagy, are gaining in strength as protective targets to prevent
neurodegeneration, together with the use of patient-derived fibroblasts to further explore
these events. These findings point out the presence of molecular damage beyond the
central nervous system (CNS) and proffer patient-derived cell platforms to the clinical
and scientific community, which enable the study of disease etiopathogenesis and
therapeutic approaches focused on modifying the natural history of PD through, among
others, the enhancement of mitochondrial function and autophagy.
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PARKINSON’S DISEASE
Parkinson’s disease (PD) is the most common movement
disorder and the second most frequent neurodegenerative disease
affecting more than 6.5 million people worldwide (Teves et al.,
2017), representing 2–3% of the population over 65 years
(Connolly and Lang, 2014; Poewe et al., 2017). As the global life
expectancy increases, the number of people with PD is expected
to rise by more than 50% in 2030, constituting an important
burden for public health (Kalia and Lang, 2015).
Although it was already known in ancient India under the
name of “Kampavata,” PD was first described in 1817 by James
Parkinson in the Essay on the Shaking Palsy and later on refined
and expanded by Jean-Martin Charcot who named the disorder
“malaldie de Parkinson”(Kempster et al., 2007; Corti et al., 2011;
Goetz, 2011). Despite PD was described more than two centuries
ago, the conceptualization of the disease continues to evolve
and it is now recognized as a systemic disease with multiple
layers of complexity.
The cardinal symptoms of PD described by James Parkinson
in 1817 and then refined by Jean-Martin Charcot, include
bradykinesia, muscular rigidity, rest tremor and postural and gait
impairment (Goetz, 2011) (Figure 1).
Pathologically, PD is a complex neurodegenerative disorder
characterized by the prominent death of dopaminergic neurons
(DAn) in the substantia nigra (SN) pars compacta (SNpc) located
in the mesencephalon and the consequent striatal dopamine (DA)
deficit that leads to the classical motor symptoms of the disease
(Kalia and Lang, 2015). In addition to the loss of DAn, another
hallmark of PD is the presence of intraneuronal inclusions
in the soma of the remaining DAn. These inclusions, named
Lewy bodies (LB) as well as Lewy neurites (LN), are collectively
referred as Lewy pathology (LP). LB are round eosinophilic
inclusions mainly formed by insoluble α-synuclein aggregates
as well as ubiquitin and other proteins (Shults, 2006). The
aggregation of these misfolded proteins has been shown to be
common to PD, dementia with LB, and multiple system atrophy
(Goedert et al., 2013).
Clinical Features
The dramatic loss of DAn in the SNpc, even in early stages
of the disease, suggests that the degeneration in this region
starts long before the motor symptoms appear (Poewe et al.,
2017). In this context, PD is considered to occur in three
stages: preclinical PD, when the neurodegeneration has started
but no clinical signs or symptoms are present; premotor or
prodromal PD, when clinical signs and/or symptoms are present
but are insufficient to establish a diagnosis of PD; and clinical
PD, when the diagnostic criteria are met (Kalia and Lang,
2015, 2016). Non-motor features are frequently present in the
prodromal phase of the disease, which can last for 20 years or
more, and involve a multitude of non-motor features including
rapid eye movement (REM) sleep behavior disorder (RBD),
constipation and hyposmia, as well as depression and anxiety
(Poewe, 2008).
In this scenario, it is now widely accepted that PD is
not a movement disorder simply induced by the loss of the
DAn in the SNpc. The SN is not the only damaged region
in PD, nor the first affected one. Brain sites other than the
SN, such as the cerebral cortex and the limbic system, have
also been reported to be impaired in patients during the
presymptomatic phase (Dickson, 2018). In fact, several studies
have shown that the degenerative process in PD is much
more extensive and affects not only the central nervous system
(CNS) but also the peripheral autonomic nervous system (PNS)
and the organs outside the brain that the latter innervates
(Braak et al., 2004). PNS dysfunction underlies the presence
of some of the specific non-motor features that appear in
the prodromal phase of PD and remain present over the
course of the disease (Jain, 2011). In line with this, LP is
not restricted to the brain but has also been encountered
in the spinal cord and PNS including the vagus nerve,
sympathetic ganglia, cardiac plexus, enteric nervous system
(ENS), salivary glands, adrenal medulla, cutaneous and sciatic
nerves (Tolosa and Vilas, 2015).
Risk Factors
Parkinson’s disease was thought to be primarily caused by
environmental factors, but research reveals that the disease
develops from a complicated interplay of ageing, genetics and
environment. In fact, the vast majority of cases occur sporadically
and genetic forms of the disease account for about 10% of patients
(Klein and Westenberger, 2012).
In general, the average age of onset of PD is the late fifties,
with a broad range from <40 to >80 years of age depending,
among others, on its pattern of inheritance. Young-onset PD is
commonly defined by an age of onset <45 years and >10% of
these cases have a genetic basis; the proportion of genetically
defined cases rises to >40% of those with disease onset before
30 years of age (Alcalay et al., 2010; Marder et al., 2010).
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FIGURE 1 | Clinical manifestations and genetic, molecular and environmental factors characteristics of Parkinson’s disease (PD). See Table 1 for the names of
genes. RBD, rapid eye movement sleep behavior disorder; PNS, peripheral autonomic nervous system; CMA, chaperon-mediated autophagy; MAMs, mitochondrial
associated membranes; NSAIs: non-steroidal antinflammatory drugs; Ca2+, calcium.
Non-genetic Risk Factors
The greatest risk factor for the development of neurodegenerative
diseases, including PD, is ageing (Kalia and Lang, 2015).
Incidence increases nearly exponentially from the sixth to the
ninth decade of life by 5–10 fold (Kalia and Lang, 2015;
Poewe et al., 2017). Total global prevalence is 0.3% and
rises with age up to 3% in those >80 years of age (Poewe
et al., 2017) (Figure 1). Many lines of evidence suggest that
some molecular pathways including mitochondrial dysfunction,
oxidative stress and abnormal cell wasting clearance (autophagy)
have a central role in both, physiological aging and age-related
neurodegenerative diseases, such as PD (Lin and Beal, 2006).
This may be especially relevant in neurons, due to its post-
mitotic nature and scarce replacement, that prone them to store
defects as they age. Accelerated or healthy aging and all factors
responsible of modulating brain fragility play a major role in PD
development, together with genetic and environmental factors.
Gender has also been reported to be a risk factor for PD,
with approximately a 3:2 male-to-female ratio. Sex hormones
have been proposed to play a neuroprotective role in the
disease. In case of female hormones, the antioxidant capacity
of estradiol, for instance, has been proposed to prevent
neurodegeneration (Aguirre-Vidal et al., 2017). Interestingly,
estradiol has also been demonstrated to activate metabolic
signaling by regulating mitochondrial function, emerging as
protective hormone in case of bioenergetic deficits (Pozdniakova
et al., 2018). The neuroprotecting role of progesterone is also
being evaluated (Bourque et al., 2019). Alternatively, gender
associated differences could also be associated to sex-associated
genetic mechanisms, to specific differences in exposure to
environmental cues or to the contribution of inequality in
health care (Kalia and Lang, 2015). Interestingly, in a few
populations, including one study from Japan, no differences in
gender, and even increased prevalence in females, was observed
(Kusumi et al., 1996). The explanation for equal gender PD
prevalence in these populations remains elusive. Dietetic, socio-
cultural, economic or even hormonal or molecular characteristics
of Japanese population (as particular mitochondrial DNA
haplogroups) may justify gender equivalence in PD development.
Other risk factors for PD are directly associated with
environmental features are pesticide exposure, rural living,
agricultural occupation, well-water drinking, prior head injury
and β-blocker use. A special mention must be done for exposure
to 1-methyl-4-phenyl-1,2,3,6-tetrahydro pyridine (MPTP), with
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similar structure of some herbicides that increase the risk of PD,
due to its historical importance. Since its incidental discovery
in drug abusers after inadvertent self-administration, MPTP
has been widely used to induce PD in animal models (Zhang
et al., 2019). MPTP is lipid-soluble molecule that penetrates the
blood–brain barrier and, once converted to its oxidized product
(MPP+), interferes with mitochondrial respiration. MPP+ acts
specifically in mitochondrial complex I, such as other toxic
PD inducers (including rotenone and pesticides). Blockade of
mitochondrial respiration has three main toxic consequences
to cells: the inhibition of ATP generation and associated
bioenergetic failure, the derived elevation of intracellular Ca2+
that promotes cell death and the promotion of oxidative stress
responsible of cell damage, all hallmarks of PD pathogenesis.
In contrast, tobacco smoking, coffee drinking, non-steroidal
anti-inflammatory drug use, calcium channel blocker intake, and
alcohol consumption have been associated with a decreased risk
of PD development (Kalia and Lang, 2015).
Additionally, the incidence of PD seems to vary within
different ethnicities. The prevalence of PD is high in Ashkenazi
Jews of Israel, Inuit, Alaska native and native American
populations (de Lau and Breteler, 2006; Poewe et al., 2017) and
only one study reports that PD is more common in Hispanic
and non-Hispanic whites compared to African Americans and
Asian in United States (Van Den Eeden et al., 2003). The
higher incidence of PD in these populations has been classically
attributed to specific genetic burden.
Genetic Risk Factors
There are two different classes of genetic contributions to PD:
gene mutations directly associated to genetically inherited forms
of PD and genetic variations, indirectly accounting for risk factors
of disease.
With respect to the first, the existence of heritable forms of
PD was originally established through the discovery in 1997
that mutations in SNCA, the gene encoding for the α-synuclein
protein, caused PD and the demonstration that α-synuclein was
the major component of LB (Corti et al., 2011). Since then, the list
of mutations causing monogenic types of PD continues to grow
associated either to dominant or recessive inherited forms of PD
(Table 1 and Figure 1). Currently 8–10% of cases are familial
(result from a genetic alteration leading to PD). They are caused
by a subset of locus usually encoded by the prefix PARK and a
number referring to their order of discovery. Those mutations
affecting genes with an autosomal recessive pattern of inheritance
usually result in early onset cases of PD, while mutations affecting
genes with dominant autosomal inheritance usually cause forms
of PD that resemble late-onset idiopathic PD.
The discovery of the molecular pathways orchestrated by
proteins encoded by these genes associated with monogenic
forms PD, have reinforced the notion that impaired
mitochondrial and autophagy homeostasis are key events
in disease etiology (Park et al., 2018). In fact, impaired
mitochondrial function and autophagy have been directly
linked to mutations of at least eleven of the genes associated to
familial PD (Table 1). Among them, Leucine-rich repeat kinase
2 (LRRK2) and Parkin (PRKN) genes emerge amongst the most
frequent forms of autosomal dominant and recessive forms of
PD, respectively.
With respect to the second, genetic risk factors of PD account
for the rest of 90–92% of non-inherited cases of PD, so-called
idiopathic. They are caused by the complex interplay of an array
of unknown factors, a part from the numerous genetic risk factors
of PD (see Table 1): modifying effects by susceptibility alleles,
environmental exposures and gene-environmental interactions
that may condition gene expression. Some of these genetic
risk factors that may conditionate the development of PD
are in common to lysosomal storage diseases, mitochondrial
pathologies or genes governing autophagic processes.
The definition of genetic and environmental cues in the
development of PD is one of the novel areas of study in which
growing and coming efforts should be focused and, probably,
thanks to the development of new generation sequencing tools,
the discovery of novel gens responsible of PD will arise, together
with new putative genetic risk factors, thus reducing the number
of idiopathic PD cases.
Table 1 includes mutations directly associated to genetically
inherited forms of PD (either of dominant or recessive
inheritance) and genetic variations indirectly accounting for risk
factors of disease. Gene name, locus and symbol have been
described, together with the protein encoded by the gene and
the function it exerts (the cell pathway governated), as well as
the kind of PD associated to the genetic mutation or variation
(responsible of early, late, sporadic or unknown onset). Among
these entities, LRRK2 and PRKN genes emerge amongst the most
frequent forms of autosomal dominant and recessive inherited-
forms of PD, respectively.
MODELS TO STUDY PARKINSON’S
DISEASE
A major challenge to study PD is the inaccessibility of the target
tissue of the disease (DAn), which is currently only available post-
mortem. In addition, by the time that clinical symptoms manifest,
most of the cells targeted by PD have already been lost (Grosch
et al., 2016). Thus, finding models that faithfully recapitulate the
events in PD is essential to understand the impaired molecular
processes that underlie the disease etiopathogenesis and its
progression. In this regard, different experimental in vitro and
in vivo models of study have been consistently used (Blesa et al.,
2012; Falkenburger et al., 2016).
Animal Models
Animal models have allowed the study of PD in vivo, partially
reproducing the specific pathogenic events and behavioral
outcomes of the disease. In fact, after the study of brain necropsies
from PD patients, much of the current understanding of the
etiology and the pathogenesis of PD has been obtained from
the study of neurotoxin-based animal models (Bezard et al.,
2013), only recently complemented by experimental approaches
targeting genes responsible of the disease. Typical cases of toxic
exposure to induce PD in animal models is the use rotenone and
MPTP exposition, which reinforced mitochondrial implication
Frontiers in Neuroscience | www.frontiersin.org 4 September 2019 | Volume 13 | Article 894
fnins-13-00894 September 10, 2019 Time: 18:27 # 5
González-Casacuberta et al. Mitoautophagic Imbalance in Cell Models of PD
TABLE 1 | Classification of genes associated with familial forms of Parkinson’s disease.
Gene name Gene symbol Gene locus Protein Protein function and cell
pathway governated
Onset of disease
Autosomal dominant inheritance Parkinson’s disease
SNCA PARK 1 or PARK4 4q22.1 Alpha-synuclein Synaptic vesicles trafficking Early
Unknown PARK3 2p13 Unknown Unknown Late
UCHL1 PARK5 4p13 Ubiquitin C-terminal hydrolase L1 Proteasome system Late
LRRK2 PARK8 12q12 Leucine-rich repeat kinase 2 Autophagy processing Late
HTRA2 PARK13 2p13.1 HtrA serine peptidase 2 Mitophagy development Unknown
VPS35 PARK17 16q12 Vacuolar protein sorting 35 Endosome regulation Late
EIF4G1 PARK18 3q27.1 Eukaryotic translation initiation factor 4 gamma 1 Protein translation Late
DNAJC13 PARK21 3q22.1 DnaJ heat shock protein family (Hsp40) member C13 Endosome regulation Late
CHCHD2 PARK22 7p11.2 Coiled-coil-helix-coiled-coil-helix domain containing 2 Mitochondria-mediated
apoptosis and metabolism
Late/Early
Autosomal recessive inheritance Parkinson’s disease
PRKN PARK2 6q26 Parkin Mitophagy development Early
PINK1 PARK6 1p36.12 PTEN-induced putative kinase 1 Mitophagy development Early
DJ-1 PARK7 1p36.23 DJ-1 Mitophagy development Early
ATP13A2 PARK9 1p36.13 ATPase cation transporting 13A2 Lysosomal function Early
GIGYF2 PARK11 2q36-7 GRB10 interacting GYF protein 2 Insulin-like growth factors
(IGFs) signaling
Early
PLA2G6 PARK14 22q13.1 Phospholipase A2 group VI Lipids metabolism Early
FBXO7 PARK15 22q12.3 F-box protein 7 Mitophagy development Early
DNAJC6 PARK19 1p31.3 DnaJ heat shock protein family (Hsp40) member C6 Endosome regulation Early
SYNJ1 PARK20 21q22.11 Synaptojanin 1 Endosome regulation Early
VPS13C PARK23 15q22.2 Vacuolar protein sorting 13 homolog C Mitophagy development Early
Risk factors for developing PD
SNCA PARK 1 or PARK4 4q22.1 Alpha-synuclein Synaptic vesicles trafficking Early




Unknown PARK10 1p32 Unknown Unknown Unknown
Unknown PARK12 Xq21-q22 Unknown Unknown Unknown
Unknown PARK16 1q32 Unknown Unknown Unknown
GBA – 1q22 Glucosylceramidase beta Lysosomal function Late
MAPT – 17q21.31 Microtubule associated protein tau Microtubule structure Sporadic
Modified from Del Rey et al. (2018).
in PD. However, toxin-based models rely on acute insults to the
nervous system and do not model the slow neural degeneration
and development of clinical manifestations characteristic of
PD (Westerlund et al., 2010) or the presence of LB, hallmark
of the disease, thus raising concerns on the recapitulation
of PD pathology.
Later, with the identification of PD-related genes, transgenic
models including yeast, Drosophila melanogaster, Caenorhabditis
elegans and murine models have been developed (Blesa et al.,
2012) as an alternative to the classical toxin-based ones.
These models enabled to gain insights in the molecular events
underlying the disease, such as mitochondrial and autophagic
deregulation, widely demonstrated in the target tissue of PD.
These models have shed light into PD pathogenic processes, but
have fallen short in replicating the phenotype and pathology
of human disease (Dawson et al., 2010). One of the main
drawbacks in the use of animal models to study PD is life span
difference between species, which may not allow reproducing
age-related events that are relevant to disease pathogenesis. On
the other hand, there is an important risk when specifically
using invertebrates to study PD as relevant pathogenic factors
are vertebrate-specific and may be absent in these models.
Finally, most of them do not recapitulate the key clinical and
neuropathological features of the disease (as trembling and
neuromelanin withdrawal in DAn). Maybe this explains why
biomarkers of disease previously verified in murine models and
treatments that have shown positive outcomes in these models,
have not later been predictive of therapeutic success in humans
(Vandamme, 2014). The biological differences between mice and
humans may be accountable for this fact, and it is an issue that
researchers must be aware of and carefully account for when
using these animal models.
In this regard, and probably due to a closer similarity, non-
human primates (NHP) have been used to generate the most
robust and clinically useful models of PD. The current gold
standard animal model of PD is a toxin-based NHP induced
Frontiers in Neuroscience | www.frontiersin.org 5 September 2019 | Volume 13 | Article 894
fnins-13-00894 September 10, 2019 Time: 18:27 # 6
González-Casacuberta et al. Mitoautophagic Imbalance in Cell Models of PD
model, which shows stable, bilateral clinical features that closely
resemble idiopathic PD (Johnston and Fox, 2014) and may even
exhibit some features of RBD (Verhave et al., 2011). However,
this model does neither recapitulate the major pathophysiological
hallmark of idiopathic PD, LB, and its utility for the study of
prodromal PD has still not been validated (Barraud et al., 2009).
The development of experimental models to elucidate disease
etiology, find novel diagnostic/prognostic biomarkers and assay
new therapeutic strategies remains as one of the most challenging
gaps in PD research.
The use of toxic or genetic animal models of disease has
strengths as reproducing the complex interplay between different
neural and non-neural brain cells directly in the target tissue of
the disease, and the assay of different therapeutic approaches in
physiologic context. Unfortunately, in parallel, animal models
fail to recapitulate important hallmarks of PD as clinical and
anatomopathological features. Other weaknesses, a part of ethical
concerns, high economic and facility costs, are that most of them
fail to reproduce the influence of aging, epigenetic, and genetic
modifying factors characteristic of PD patients. Novel cell models
overcome part of these limitations.
Cell Models
Immortalized cell lines of neural origin, either animal or human,
that can also be subjected to toxin exposition or gene editing, have
been widely used to model PD (Obinata, 2007). These cell models
have provided consistent and reproducible results. Among their
main strengths there is their identical genetic background that
confers them a large homogeneity (Carter and Shieh, 2015).
Moreover, they represent wide platforms for disease modeling
due to low cost maintenance and editing easiness. One example
is the human-derived neuroblastoma cell line SHSY5Y that can
be used undifferentiated or differentiated to DAn to model PD
(Lopes et al., 2010; Alvarez-Erviti et al., 2011).
However, immortalized cell lines are also associated to
important weaknesses including the presence of genetic
instability or the high rate of glycolytic metabolism which
pushes toward the use of patient-derived cell models
(Frattini et al., 2015).
The fact that the greatest proportion of PD is of unknown
cause and the urgent need to find novel biomarkers at
the prodromal phase of the disease has encouraged the
development of specific patient-derived models. The advantages
of these patient-derived cell models is that they recapitulate PD
pathogenicity at an individual basis, thus partially circumventing
the drawbacks of animal and established cell line models (Teves
et al., 2017). In this context, the use of patient-derived cells that
conserve patient-specific features has constituted a substantial
progress in the study of PD, considering the great complexity and
individual variability of the disease that encompasses unknown
genetic and epigenetic factors, including aging, as well as
environmental insults, has been recapitulated.
The use of patient-derived neural stem cell models has stirred
up the field of PD research. Some works on PD have been
done directly studying these stem cells (Sanberg, 2007) and
some others by differentiating them into neural precursors or
mature neurons (Le Grand et al., 2015; Yang et al., 2017). For
instance, neural precursors as neurosphere models (free-floating
clusters of neural stem cells) are widely used for the study of
neuronal differentiation and neuronal disease (Matigian et al.,
2010). For the study of mature-derived neurons, the development
of induced pluripotent stem cells (iPSCs) has spawned a new
approach to model PD allowing researchers to generate disease-
specific DAn in vitro by reprograming somatic cells from patients
with the disease (Fernandez-Santiago and Ezquerra, 2016). It
is expected that the access to iPSCs-derived neurons from
PD patients will shed light into mechanistic insights of PD
pathogenesis and serves as a platform for drug screening and
early diagnosis.
One of the latest applications of iPSC is the generation
of different brain cell lineages to create brain organoids that
resemble neuronal architecture, self-organization and cell to
cell interaction from the physiologic brain. They are three-
dimensional (3D) in vitro culture systems that recapitulate the
developmental processes and organization of the developing
human brain. These “mini-brains” provide a physiologically
relevant model for the study of neurological development and
disease processes that are unique to the human nervous system,
together with other 2D and 3D models including neurospheres,
neural aggregates, neural rosettes, and cortical spheroids. They
all are emerging and promising models for the study of
brain fragility and neurodegenerative diseases that will bring
light into PD field in the next coming years but that are
currently handicapped because of their novelty and setting up
troubleshooting (Schwamborn, 2018).
Additionally, and despite being an exciting prospect for PD
research, stem cell-derived neural lines and iPSC technologies
have some other important inconveniences, including a
considerable phenotypic variability unrelated to their genotype
and their high maintenance costs and time-inefficiency (Jacobs,
2014). Additionally, stem cell or iPSC differentiation into
neurons generally leads to low yields of DAn generation
(Jacobs, 2014) thus obtaining heterogeneous cell pools where
undifferentiated and DAn-derived cell types coexist (Fernandez-
Santiago et al., 2015). Of note, whilst stem cells and iPSCs
reprogramed from somatic cells highly rely on glycolytic
metabolism, neurons are mainly energetically sustained by
mitochondrial oxidative metabolism. In this scenario, one of
the limitations of these cell models is the analysis of certain cell
processes such as bioenergetics, oxidative stress or autophagy
may become biased due to this confounding factor. Additionally,
the genetic manipulation required to generate iPSC-derived
DAn is frequently associated to genetic aberrations (e.g., copy
number variations, somatic coding mutations, and chromosomal
defects). Thus, the development of alternative patient-derived
cell models is gaining in strength.
As previously mentioned, accumulating evidences suggest that
PD is a multisystem disorder rather than a solely dopaminergic
motor syndrome that encompasses central and peripheral clinical
features (Djaldetti et al., 2009; Cersosimo and Benarroch, 2012).
In line with this, PD pathological and molecular changes are also
not confined in the CNS but are also present in the PNS and
the organs that the latter innervates (Djaldetti et al., 2009). For
instance, a great number of studies have reported α-synuclein
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deposits in many different peripheral tissues derived from PD
patients (Tolosa and Vilas, 2015). On the other hand, many other
alterations at molecular level including transcriptional changes,
mitochondrial dysfunction and associated increased oxidative
stress as well as autophagy deregulation have been described
in PD-derived peripheral tissues such as muscle (Cardellach
et al., 1993), blood cells including platelets and leukocytes (Haas
et al., 1995; Muftuoglu et al., 2004; Mutez et al., 2014) and
fibroblasts (Mortiboys et al., 2010; González-Casacuberta et al.,
2018; Juarez-Flores et al., 2018), supporting the use of novel
peripheral approaches.
The use of patient skin-derived fibroblasts has been
widely utilized to model numerous diseases of metabolic,
neurodegenerative, and lysosomal origin (Solini et al., 2004;
McNeill et al., 2014; Alvarez-Mora et al., 2017; Konrad et al.,
2017). For mitochondrial diseases, fibroblasts constitute the
model of choice to diagnose and often to support research of
these entities (Cameron et al., 2004; Soiferman and Saada, 2015;
Ferrer-Cortès et al., 2016). Several studies in PD have used human
skin-derived fibroblasts to investigate the molecular mechanisms
underlying disease etiopathogenesis (Auburger et al., 2012).
Skin-derived fibroblasts offer considerable advantages (Table 2):
they constitute a patient-specific cellular system that retains
the genetic (mutations, polymorphisms, polygenic risk factors,
etc.) and epigenetic background of the patients while potentially
preserving the specific environmental, toxic and cumulative
age history. They show relevant expression of most PD genes
which make them also suitable for the study of monogenic forms
of PD (Auburger et al., 2012; Ivanov et al., 2016). Since they
are accessible peripheral cells, they can be obtained from PD
patients and healthy controls through an easy and minimally
invasive procedure. Furthermore, fibroblasts can be propagated
in culture, frozen, and stored for long periods of time, and
transformed in cell types that exhibit molecular characteristics of
TABLE 2 | Advantages and disadvantages of using skin-derived fibroblasts as a
cell model to study PD.
Advantages Disadvantages
• Low facility and maintenance costs
• Easy to obtain, propagate, maintain
and store
• Maintain genetic and epigenetic
background of the patients
• Reflect environmental cues and
age-related events of patients
• Relative poor invasiveness of the
procedure
• Presents relevant expression of most
PARK genes
• As primary cells, do not exhibit
maximal glycolisis
• Can be genetically manipulated to
be reprogrammed to iPSCs and
redifferentiated to dopaminergic
neurons or to perform gene silencing
or protein rescuing experiments
• As mitotic cells exhibit high renewal
rates in contrast to the postmitotic
nature of neural tissue
• Not part of the central nervous
system
• Mixed metabolism (glycolitic and
oxidative) to obtain cell energy
• Mycoplasma contaminations are
frequent and may lead to artificial
phenotypes
• Pure fibroblast culture is not
achieved until passage 3
• Growing fibroblasts can be at
different cell cycle phases
representing a confounding factor
Modified from Auburger et al. (2012).
the target tissue of the disease. It should be noted that fibroblasts
make dynamic cell-to-cell contacts when cultured, which is
similar to neuronal cells (Konrad et al., 2017).
Studies in skin-derived fibroblasts from patients with sPD
have thrown relevant and consistent information regarding
molecular pathways altered in this type of neurodegeneration.
A recent study showed that fibroblasts from sPD patients
have higher growth rates, altered morphology, increased
mitochondrial susceptibility to UV-exerted stress and autophagic
alterations (Teves et al., 2017).
Other works focused on the study of molecular alterations
in monogenic-PD patient fibroblasts have reported disease-
relevant changes further supporting the adequacy of this
model to study these forms of the disease. These changes
include altered transcript (González-Casacuberta et al., 2018)
and protein expression (Lippolis et al., 2015; Azkona et al.,
2016), SNCA gene expression up-regulation (Hoepken et al.,
2008), altered GCase enzyme activity (McNeill et al., 2014),
microtubule destabilization (Cartelli et al., 2012), impaired
autophagy (Dehay et al., 2012; Rakovic et al., 2013; Juarez-
Flores et al., 2018), increased sensitivity to neurotoxins (Yakhine-
Diop et al., 2014), bioenergetic deficits (Papkovskaia et al., 2012;
Ambrosi et al., 2014; Juarez-Flores et al., 2018), mitochondrial
alterations (Mortiboys et al., 2008, 2010), and enhanced apoptosis
(Klinkenberg et al., 2010; Romani-Aumedes et al., 2014).
In summary, skin-derived fibroblasts show certain
disadvantages (see Table 2) but constitute, at the same
time, a patient-specific cellular system that, without genetic
manipulation, can potentially recapitulate the main features
of the disease (Auburger et al., 2012). In fact, many of the
molecular hallmarks occurring in nigral DAn have been reported
in fibroblasts from patients with sporadic and monogenic forms
of the disease (Hoepken et al., 2008; Mortiboys et al., 2010;




OXIDATIVE STRESS AND AUTOPHAGY
IMPAIRMENT
Most of accumulated evidences derived from studying brains of
PD patients, animal or cell models of disease stand for common
molecular mechanisms underlying PD pathogenesis. Among
them, neuroinflammation, apoptosis, proteasomal dysfunction,
and especially mitochondrial impairment, reactive oxygen
species production (ROS) and autophagic failure, emerge as
key players in PD development. However, there are different
schools of thought regarding the triggers of the disease. Two
main hypotheses raised: according to the “protein depot cascade
hypothesis,” alpha-synuclein and other misfolded proteins stored
as protein depots in neurons are the cause of PD. Other stand for
the “mitochondrial cascade hypothesis,” that foresees the origin
of PD in a defect in the oxidative phosphorylation (OXPHOS)
system. Interestingly, protein deposition and bioenergetics
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appear to be closely related. Thus, alpha-synuclein can reduce
OXPHOS function and OXPHOS deficiency can increase alpha-
synuclein production (Cardoso, 2011; Haelterman et al., 2014).
In line with the “mitochondrial cascade hypothesis,”
some primary mitochondrial diseases caused by monogenic
mutations in mitochondrial-related genes that usually translate
to OXPHOS deficiencies, clinically manifests as brain disease
such as neurodegeneration and parkinsonism (Diez et al.,
2017; Suomalainen and Battersby, 2017). In fact, mitochondria
contribute to neurodegeneration through deficiencies in the
mitochondrial respiratory chain (MRC) or OXPHOS and
associated overproduction of ROS, as well as the accumulation
of mitochondrial DNA (mtDNA) mutations or defects in its
quality (deletions) or quantity (depletion) (Suomalainen and
Battersby, 2017). Many evidences point out that mitochondrial
dysfunction-derived oxidative stress is mainly centralized at the
level of the MRC complexes I and III and play a central role in
brain damage of PD patients (Poewe et al., 2017) (Figure 1).
The study of mitochondrial contribution to PD and other
neurodegenerative diseases has been widely validated by the
use of cybrids (Ghosh et al., 1999; Llobet et al., 2013). They
allow the exploitation of mutation-independent, mitochondrial-
derived impairments (age-associated, mostly). Arduíno et al.
described the generation of cytoplasmic hybrid cells (or cybrids)
as a promising cellular model for the study of sPD. This approach
consists on the fusion of platelets harboring mtDNA from sPD
patients with cells in which the endogenous mtDNA has been
depleted (Rho0 cells). This allows the comparison of different
mtDNAs in the same nuclear context. The sPD cybrid model
has been successful in recapitulating most of the hallmarks of
sPD (including CI dysfunction, ROS generation, loss of calcium
homeostasis, changes in mitochondrial morphology, increased
proton leak and decreased maximal respiratory capacity, as well
as protein aggregation in the form of Lewy body-like inclusions)
(Swerdlow et al., 1996; Cassarino et al., 1997; Sheehan et al., 1997;
Ghosh et al., 1999; Trimmer et al., 2004; Esteves et al., 2009,
2010a,b; Arduíno et al., 2012, 2013; Llobet et al., 2013), thus
constituting a validated model for addressing the link between
mitochondrial dysfunction and sPD pathology.
Mitochondrial function is essential in almost all cells of
the organism, but specially in neurons. There are different
reasons to explain their dependence on proper mitochondrial
function, controlled oxidative stress production and adequate
mitochondrial replacement through autophagy.
Neural metabolism is highly oxidative. Glucose is the
obligatory energy substrate of the adult brain. However,
under certain circumstances the brain has the capacity to
use alternative blood-derived energy substrates, such as ketone
bodies (during starvation or development) (Magistretti, 2006)
and lactate (during periods of intense physical activity) (van
Hall et al., 2009). Once inside the cell, glucose can be
metabolized through glycolysis (leading to lactate production or
mitochondrial metabolism) or through the pentose phosphate
pathway (as glycogenesis can only be performed in astrocytes).
Both mitochondrial metabolism and pentose phosphate pathway
are the proper bioenergetic pathways enhanced in physiologic
conditions to provide of ATP and antioxidant power to the
cell, respectively. Contrarily, the metabolic activation of lactate
production through the anaerobic glycolysis may be detrimental
for long-term neuronal function and should be only sustained in
certain punctual circumstances (Falkowska et al., 2015).
Metabolic oxidative activity of neurons explains they
dependence on mitochondria to obtain energy. Noticeably, brain
is one of the highest energy-demanding organs of the body
due to the its intrinsic physiological activity. It is constituted
by postmitotic cells (neurons) with less capacity for cellular
regeneration compared to other organs. Thus, it is believed to
be particularly vulnerable to mitochondrial dysfunction, ROS
damaging effects and detrimental autophagic renewal of cell
components, that may explain why is prone to manifest clinical
evidences of mitochondrial, oxidative or autophagic alterations
(Picard and McEwen, 2014). This is especially relevant in the case
of DAn that synthesize the most pro-oxidant neurotransmitter of
the CNS (DA), thus becoming especially vulnerable to oxidative
environments, mitochondrial failure or autophagic imbalance.
In this scenario, mitochondrial dysfunction, associated
oxidative stress and autophagic development becomes critical
for neuronal survival. Several lines of evidence have implicated
mitochondrial dysfunction as a key element in PD pathogenesis.
Reduction of mitochondrial CI activity has been reported in
several tissues isolated from PD patients including the CNS
(Schapira and Gegg, 2011). In addition, the target genes of
the mitochondrial master transcriptional regulator PGC1α have
been reported to be under expressed in PD, together with
strong evidences of increased oxidative stress and reduced
autophagic function that may be finally responsible for defective
mitochondrial and protein depot (Schapira and Gegg, 2011;
Nixon, 2013; Siddiqui et al., 2015).
Unfortunately, when postmortem brain tissue of PD patients
is studied, most of DAn have disappeared (Teves et al., 2017),
thus difficulting the establishment of any potential etiologic
causal link. In consequence, the study of experimental models
of PD conveys the opportunity to foresee the triggers of
neuronal degeneration.
As previously mentioned, initial models of PD were developed
by using MPTP, a mitochondrial neurotoxin that specifically
targeted DAn in primates and mice which was discovered to
produce parkinsonism in humans (Langston, 2017). MPTP-based
models and many other models using mitochondrial neurotoxins
such as 6-hydroxydopamine (6-OHDA), rotenone or paraquat,
have been used over the past years in the PD research field to
replicate features of disease neuropathology (Jagmag et al., 2015).
On the other hand, the depletion of mitochondrial proteins in
mice that are essential for mtDNA maintenance (TFAM and
En1) leads to neuronal degeneration of DAn in the SN which
accounts for the development of several important features of PD
neuropathology (Pickrell et al., 2013).
In PD patients, reduction of mitochondrial CI activity has
been reported in several isolated tissues including the SN and
peripheral tissues (Schapira and Gegg, 2011). In addition, the
downregulation of the target genes of the master transcriptional
regulator involved in mitochondrial biogenesis (peroxisome
proliferator-activated receptor gamma coactivator 1-alpha or
PGC-1α) have been reported in PD (Siddiqui et al., 2015). Low
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levels of α-synuclein have been encountered in mitochondria
in physiologic conditions and in vitro abnormal accumulation
of this protein has proven to lead to mitochondrial CI
dysfunction and associated oxidative stress, importantly linking
these two events that have been repeatedly reported in PD
(Poewe et al., 2017).
Different levels of ROS damage have been reported within the
target brain region that undergoes selective neurodegeneration
in PD. Specifically, lipid peroxidation markers such as 4-
hydroxynonenal and malondialdehyde, have been identified in
the SN of PD patients (Dias et al., 2013). However, it remains
elusive whether oxidative stress occurs early in the disease or
later during the decease of neurons and thus, as a consequence
of cell degeneration.
Mitochondria are not isolated or static entities but instead are
highly dynamic organelles that are transported on cytoskeletal
proteins responsible for mitochondrial trafficking and are
continuously subjected to fusion and fission processes in order to
maintain their homeostasis (Johri and Beal, 2012). Mitochondrial
dynamics have also been reported to be altered in PD (Van
Laar and Berman, 2009). Similarly, mitochondrial turnover and
quality control through selective autophagy (mitophagy), or
mitochondrial relationship with other organelles as endoplasmic
reticulum and its associated membranes (MAMs) have also been
associated to PD (Hattori et al., 2017). Mitochondrial dysfunction
and oxidative stress are associated with the impairment of
the autophagy process through the accumulation of damaged
mitochondria due to their defective turnover and through
depletion of lysosomes, evidencing that different molecular
pathways involved in PD pathogenesis are intimately related
(Poewe et al., 2017).
Although our understanding of the regulatory pathways that
control autophagy is still limited, recent advances have shed light
on the importance of autophagy in a panoply of physiological
processes and human diseases including neurodegeneration
(Jing and Lim, 2012). The post-mitotic status of neurons
prone them to be strictly dependent on optimal regulation
of autophagy for the removal of dysfunctional or obsolete
cell constituents, especially as the brain ages. In fact, the
most prevalent pathological feature of many neurodegenerative
diseases is the aggregation of misfolded proteins and the loss of
certain neuronal populations (Guo et al., 2018), closely related
to lysosomal function. This becomes more evident with the
observation that the brain is often the most severely affected
organ in primary lysosomal disorders and that mutations in
genes involved in autophagy are causatively linked mechanisms
to neurodegenerative disorders with exceptional frequency. This
link between lysosomal performance and neurodegenerative
diseases explains the high prevalence of genetic lysosomal
variants that are found in PD by genome wide association studies
(Levine and Kroemer, 2019).
On the other hand, it has been reported that in
neurodegenerative disorders, such as Alzheimer’s disease,
amyotrophic lateral sclerosis and familial PD, defects arise at
different stages of the autophagy pathway and have different
implications for pathogenesis and therapy (Nixon, 2013). Recent
research in the field of PD points out to alterations in specific
steps of autophagic processes that could be of high relevance
in the etiopathogenesis of the disease (Jing and Lim, 2012;
Nixon, 2013; Guo et al., 2018) (Figure 1). For instance, an
upregulation of macroautophagy following an overwhelmed
chaperone-mediated autophagy (CMA) system as a result of
overexpression of misfolded aggregates of α-synuclein has been
shown in mice and in vitro PD model systems (Spencer et al.,
2009; Yu et al., 2009; Ebrahimi-Fakhari et al., 2011). Moreover,
an accumulation of autophagosomes (AP) and an early decrease
in lysosome content as a result of lysosomal membrane
destabilization and cytosolic release of cathepsins has been
reported in DAn of a neurotoxin-based mouse model (Dehay
et al., 2010). In addition, a decrease in lysosomal acidification
and consequent decline of lysosomal protein turnover has been
reported in mice overexpressing α-synuclein (Stefanis et al.,
2001; Cuervo et al., 2004).
In post mortem brain samples of PD patients dysfunctional
lysosomes and accumulation of AP were observed in
neurons, indicating a pathogenic role of autophagy in PD
(Guo et al., 2018).
Mitochondrial Dysfunction, Oxidative
Stress, and Autophagy Disruption in
Familial PD
Amongst all familial forms of PD, late and early onset PD
associated to mutations in LRRK2 and PRKN genes, respectively,
are responsible for the most frequent dominant and recessive
inherited forms of PD. These genes have emerged as promising
examples of disease due to their established role in commanding
bioenergetic and autophagic balance (Figure 2).
Numerous genes responsible of inherited PD cause the
impairment of essential functions for mitochondrial homeostasis:
OXPHOS function, mitochondrial trafficking, oxidative stress,
calcium imbalance, mitochondrial biogenesis, mitochondria
dynamics and mitochondrial autophagy.
LRRK2-Associated PD (LRRK2-PD)
The LRRK2 gene (at the PARK8 locus) is located in chromosome
12, contains 51 exons and spans a genomic distance of 144 kb
that includes 7500 nucleotides of coding sequence. Up to date,
about 80 “probably pathogenic” and seven pathogenic LRRK2
mutations have been described, being the G2019S (G2019S-
LRRK2) the most frequent pathogenic mutation (Corti et al.,
2011). Most of LRRK2 mutations correspond to missense
variants, which, along with the dominant inheritance, are
consistent with a gain-of-function pathogenic mechanism (Corti
et al., 2011). A number of non-pathologic variants are also
known and some others variants that may act as PD risk
factors have been reported using genome wide association studies
(Islam and Moore, 2017).
LRRK2 encodes a 2527 amino-acid multi-domain protein
(LRRK2), which is also known as dardarin, from the Basque
word “dardara” which means trembling. LRRK2 has the particular
feature of encoding a leucine-rich repeat (LRR), a ROC-COR
GTPase, a mitogen-activated protein kinase, and WD40 domains
in the same protein (Singh et al., 2019) (Figure 3). Of note,
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FIGURE 2 | Mitochondrial effects of genetic mutations associated to familial PD. Modified from Park et al. (2018).
FIGURE 3 | Schematic representation of the LRRK2 protein showing its functional domains and the most frequent pathogenic missense point mutations responsible
for PD.
pathogenic mutations appear to be located in functionally
relevant regions of the protein such as in the specific case of
the G2019S-LRRK2 mutations that affect the kinase domain
making it more active (Corti et al., 2011) (Figure 3). LRRK2
is expressed in most organs including brain, heart, liver, and
circulating immune cells.
Mutations in LRRK2 account for∼10% of familial PD and for
a significant fraction of sPD cases (Kalinderi et al., 2007). LRRK2
mutation frequencies vary between ethnic groups, being North
African Arabs and Ashkenazi Jews the most affected populations
(Correia Guedes et al., 2010). The G2019S-LRRK2 mutation is
responsible for 1% of apparent sPD and 4% of familial PD
worldwide (Healy et al., 2008). Importantly, even when proven
pathogenic mutations are present, penetrance is age dependent
and estimated between 30 and 74% (Ozelius et al., 2006). This
fact makes the LRRK2-mutation carriers a very interesting target
of study, as they present a subclinical stage with molecular
alterations potentially determinant for disease progression.
Clinically, LRRK2-associated PD (LRRK2-PD) presents with a
PD-typical phenotype with no sex association. A large systematic
review of LRRK2-PD case reports that age of onset is around
57 years, with a mean disease duration of 10 years. The cardinal
PD symptoms were reported with the following frequency:
bradykinesia in 99%, rigidity in 99%, tremor in 88% and postural
instability in 65%, while atypical signs of PD have been reported
only anecdotally. In addition, autopsies of such patients showed
prominent loss of melanized DAn in the SNpc (Trinh et al.,
2018). Disease progression is slow and response to treatment
is as good as in sPD (Corti et al., 2011). LRRK2-PD has
demonstrated an unprecedentedly significant role of LRRK2 in
PD pathogenesis as most of the clinical and pathological features
are indistinguishable from those of sPD (Gosal et al., 2005). Thus,
since its discovery, great efforts have been focused on the study of
this form of the disease.
Within cells, LRRK2 associates with various intracellular
membranes and vesicular structures including the endosomes,
the lysosomes, the multivesicular bodies, the outer mitochondrial
membrane (OMM), lipid rafts, microtubule associates vesicles,
Golgi complex, and the endoplasmic reticulum (Cookson, 2012),
thus it is highly associated to MAMs. Accordingly to its
multi-domain nature, LRRK2 has been implied in many cellular
functions such as cytoskeleton remodeling, vesicle trafficking and
movement, protein translation, autophagy and mitochondrial
function homeostasis (Cookson, 2010; Liu et al., 2012; Taymans
et al., 2015; Roosen and Cookson, 2016; Juarez-Flores et al.,
2018; Price et al., 2018). Specifically, studies consisting of
modifications in the expression of LRRK2 in different neural-
cell based models have reported an altered synaptic vesicle
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trafficking and endocytosis (Shin et al., 2008; Piccoli et al.,
2011). LRRK2 dysfunction has also been demonstrated to play
a role in different pathologic scenarios, such as ∝-synuclein
phosphorylation, microtubule dynamics, alterations in the
uncoupling protein system (UPS) as well as in neurite growth
and branching regulation that may trigger neurodegeneration
(Dächsel et al., 2010). Silencing of LRRK2 reduced the
inflammatory response in different human cell-derived and
animal models (Lopez de Maturana et al., 2014).
A growing body of evidence supports a role for LRRK2 in
mitochondrial dynamics and function. In fact, it interacts with a
number of crucial proteins that regulate mitochondrial dynamics
such as dynamin-related protein1 (DRP1), Mitofusin (MFN1)
and 2 and optic atrophy1 (OPA1) (Wang et al., 2012; Stafa
et al., 2014; Park et al., 2018). Thus, LRRK2 might directly
affect mitochondrial homeostasis while indirectly regulating it
through autophagy and cytoskeletal dynamics (Singh et al., 2019).
This hypothesis is also supported by many studies reporting
mitochondrial dysfunction in various animal models of G2019S-
LRRK2 PD, in postmortem human tissues from LRRK2-PD
patients (Mortiboys et al., 2010; Cooper et al., 2012; Sanders
et al., 2014; Yue et al., 2015) and in different patient-derived
cell models (Niu et al., 2012; Wang et al., 2012; Cherra
et al., 2013; Su and Qi, 2013). Such studies reported mtDNA
damage, decreased mitochondrial membrane potential (MMP)
and ATP production, as well as altered mitochondrial dynamics
and mitophagy (Singh et al., 2019). In addition, a protective
role against oxidative stress has been reported for wild-type
LRRK2, which seems to be lost in mutant forms of the protein
(Liou et al., 2008).
Studies in Fibroblasts From LRRK2-Associated PD
Mitochondrial phenotypes have been characterized in LRRK2-
fibroblasts at baseline and under conditions of pharmacological
stress. The most common pharmacological approaches used to
date include mitochondrial toxins such as MPTP, valinomycin,
oligomycin, CCCP, and rotenone. As these approaches may
mimic mitochondrial toxicity, they are far from dissecting the
mitochondrial pathways affected under physiological conditions
(Trentadue et al., 2012). Smith et al. (2015) demonstrated
an increased sensitivity to valinomycin in a subset, but
not all, of fibroblasts derived from PD patients, pinpointing
again the great interindividual variability of the disease and,
outstandingly, that the molecular characteristics of patient-
derived cell models do not always correlate with the clinical
presentation of the disease.
Mortiboys et al. (2010) reported for the first time
mitochondrial alterations in fibroblasts of human G2019S-
LRRK2 mutation carriers, consisting of reduced MMP, reduced
intracellular ATP levels, mitochondrial elongation and increased
mitochondrial interconnectivity. These findings were further
confirmed by Papkovskaia et al. (2012), who described decreased
MMP and ATP levels as well as increased proton leakage
and ROS levels with the associated increase in uncoupling
protein 2 (UCP2) in fibroblasts from G2019S-LRRK2 PD
patients. Several studies have repeatedly observed alterations
in mitochondrial dynamics such as increased mitochondrial
fragmentation in fibroblasts from LRRK2-PD patients (Su
and Qi, 2013; Grünewald et al., 2014; Smith et al., 2015;
Falkenburger et al., 2016).
A recent study compared mitochondrial function and
autophagy in fibroblasts of G2019S-LRRK2-mutation carriers
without clinical symptoms (so called non-manifesting carriers
or NMC), with patients harboring G2019S-LRRK2-mutation
and clinical manifested PD. Interestingly, fibroblasts of NMC
showed an enhanced mitochondrial performance upon forcing
mitochondrial oxidative metabolism with galactose and
upregulation of autophagy (Juarez-Flores et al., 2018). These
findings suggested that the exhaustion of the bioenergetic and
autophagy reserve might contribute to the onset of clinical PD
symptoms. Other authors have reported heightened autophagic
flux and higher expression of autophagy markers as well as an
increased mitophagy in G2019S-LRRK2-mutation carriers with
clinical diagnosed PD (Smith et al., 2015; Su et al., 2015). The
reduction in mitophagy and increased ROS production has been
associated to defective histone acetyltransferase and deacetylase
activities contributing to cell death also in LRRK2-fibroblasts
(Yakhine-Diop et al., 2019). Additionally, the novel role of key
regulators of autophagy (as TMEM230) interacting with Rab
proteins as Raba or Rab32been described in LRRK2-patients
fibroblasts is emerging as a promising new target in disease
(Waschbüsch et al., 2014; Kim et al., 2017).
PRKN-Associated PD (PRKN-PD)
Other forms of PD have also been genetically associated to
mitochondrial and autophagic imbalance, in this case through a
recessive inheritance. This is the case of PRKN.
The locus of PRKN is mapped to the telomeric region
of the long-arm of chromosome 6. More than 170 different
mutations have been identified throughout the sequence of
this particularly large gene (1.35 Mb) ranging from point and
missense mutations to large deletions or multiplications and
small deletions/insertions (Bruggemann and Klein, 1993; Klein
and Westenberger, 2012) (Figure 4). Rare deletions extending in
the neighboring PRKN coregulated gene (PACRG) result in the
same early onset parkinsonism phenotype (Corti et al., 2011).
PRKN is a 465 amino acid protein that contains an NH2-
terminal homologous to a ubiquitin-like domain (UBL) followed
by three really interesting new gene (RING) finger domains
(RING 0–2) separated by an In-Between-RING (IBR) domain in
the COOH-terminal part, each of which bind two Zn2+ (Zhang
et al., 2015) (Figure 4). Functionally, PRKN is a member of a
family of E3 ubiquitin protein-ligases responsible for the labeling
of selected cargos, such as obsolete proteins and organelles, which
need to be degraded through the ubiquitination process. This
process comprises the transfer of activated ubiquitin molecules
to the lysine residues of specific substrate proteins. Depending
on the site and type of ubiquitination (mono, poly or multi-
ubiquitination), certain cell signaling processes are activated,
including proteosomal degradation but also non-degradative
signaling roles (Dawson and Dawson, 2010).
Along with the original discovery of the PRKN function as
an E3 ubiquitin ligase in PD-associated PRKN mutations, the
hypothesis that loss of PRKN function would lead to the toxic
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FIGURE 4 | Schematic representation of the Parkin protein showing its functional domains and the most frequent pathogenic missense point mutations responsible
for PD. Dozens of alternative frameshift and nonsense mutations, insertions, deletions, duplications or triplications have also been associated to disease.
accumulation of one or several of its substrates raised. To date,
no less than 25 PRKN putative substrates have been reported and
new substrates continue to emerge periodically, especially those
related to mitochondria (Zhang et al., 2015). In addition, many
dynamically regulated ubiquitination sites in dozens of proteins
have been identified, with strong enrichment for OMM proteins,
indicating that PRKN dramatically alters the ubiquitination
status of the mitochondrial proteome (Sarraf et al., 2013).
Nigral cell loss in PRKN-PD patients appears to be caused by
a loss of function of the protein due to biallelic homozygous or
compound heterozygous mutations in the PRKN gene. However,
there is an ongoing debate with regard to whether heterozygous
PRKN mutations may confer increased susceptibility to PD as
heterozygous PRKN pathogenic variants have been detected in
a large number of individuals with PD (Bruggemann and Klein,
1993; Mortiboys et al., 2008).
Although the population-based prevalence of PRKN-PD is
largely unknown (Bruggemann and Klein, 1993), it is thought
that PRKN mutations account for up to 50% of recessive
familial forms and 80% in those patients with a PD onset
before the age of 20 years (Corti et al., 2011). Women and
men are equally affected, with an age at onset usually <40–
50 years (Mizuno et al., 2001) although some individuals
may not develop PD until age 60 or 70 years (Klein et al.,
2000; Lohmann et al., 2003). In addition to an earlier age at
onset, PRKN-PD patients show a clinical phenotype similar to
that of sPD being bradykinesia and tremor amongst the most
common signs, but also a number of specific clinical features.
PRKN-PD is also characterized by a relatively benign course
with slow progression, remarkable and maintained response to
low levodopa doses but with frequent severe treatment-related
motor complications such as early motor fluctuations and the
development of dyskinesias (Cheon et al., 2012). Pyramidal signs,
cerebellar features, and psychiatric disorders have been reported,
but dementia or dysautonomia seem to be rare (Corti et al., 2011;
Johansen et al., 2018).
In the limited neurophathologic studies, PRKN mutations are
associated with selective DAn loss in the SN and some cases
reported a moderate decrease of noradrenergic neurons in the
Locus coeruleus with gliosis and without LB. However, a few
cases of LP have been reported in PRKN-PD, especially those
associated to a later onset of the disease (Bruggemann and Klein,
1993; Johansen et al., 2018).
One of the best characterized functions of PRKN is its role
in the process of mitophagy, which is the selective targeting of
a damaged mitochondrion for autophagy. Compelling evidence
suggests that PRKN acts together with and downstream of PINK1
in a common mitochondrial quality control pathway responsible
for the detection and clearance of damaged mitochondria
through mitophagy (Eiyama and Okamoto, 2015). In healthy
mitochondria, PINK1 is constitutively imported into the OMM
and inner mitochondrial membranes (IMM), cleaved by several
proteases and subsequently degraded. Loss of MMP impedes
the import of PINK1 in the IMM, thereby stabilizing PINK1
on the OMM and consequently recruiting PRKN from the
cytosol. In its native state, PRKN is auto-inhibited by its
N-terminal UBL domain, which blocks the binding site for
any incoming E2 ubiquitin conjugate, required for PRKN
ubiquitination activity. Upon mitochondrial depolarization,
PINK1 phosphorylates cytoplasmic PRKN in its UBL domain,
relieving PRKN autoinhibition (Eiyama and Okamoto, 2015).
Activated PRKN ubiquitinates many OMM proteins including
VDAC1, mitofusins and the translocase of the OMM 20
(TOMM20) (Kondapalli et al., 2012; Ivankovic et al., 2016).
Together, PINK1 and phosphorylated PRKN extensively modify
the OMM with phosphorylated ubiquitin (pUb) chains. pUb
chains serve as a mitochondrial receptor for further allosteric
activation and recruitment of PRKN to the OMM, resulting
in a self-amplifying feed-forward loop. Ubiquitination of these
substrates primes mitochondria for recruitment to phagophores
that then mature to AP and fuse with lysosomes resulting
in the degradation of dysfunctional mitochondria (Ichimura
et al., 2013). In addition, recent evidence suggests that PRKN
is also involved in the aggresome-autophagy pathway in which
PRKN promotes the sequestration of misfolded proteins into
aggresomes and its subsequent clearance by autophagy (Olzmann
and Chin, 2008; Yung et al., 2016).
On the other hand, PRKN has been implicated in
mitochondrial biogenesis specifically, through the regulation
by ubiquitination of the protein levels of one of its substrates
named PARIS (ZNF746) (Shin et al., 2011). PARIS represses the
expression of the transcriptional coactivator PGC-1α, which
is considered a master regulator of mitochondrial biogenesis.
In this line, PARIS has been reported to accumulate in models
of PRKN inactivation and in human PD brain (Shin et al.,
2011). Thus, PRKN potentially acts as an intermediary between
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mitochondrial biogenesis and autophagy, by both blocking
mitochondrial biogenesis and mitochondrial turn-over, thus
resulting in mitochondrial aging.
Studies in Fibroblasts From PRKN-PD Patients
Amongst all the studies using skin-derived fibroblasts as a cell
model for PRKN-PD, it is worth stressing that many of them
have focused on studying mitochondrial function leading to
controversial outcomes.
Alterations in the enzymatic activities of the MRC have been
previously reported in PRKN-PD fibroblasts (Mortiboys et al.,
2008; Grunewald et al., 2010; Pacelli et al., 2011). Mortiboys et al.
(2008) and Pacelli et al. (2011) described CI enzymatic deficiency
in PRKN-PD fibroblasts, while Grunewald et al. (2010) observed
preserved enzymatic activities in isolated mitochondria from a
larger cohort (Mortiboys et al., 2008; Grunewald et al., 2010;
Pacelli et al., 2011). Mitochondrial complex IV deficiency has
only been described by Pacelli et al. (2011) in two PRKN-PD
fibroblasts lines while others have reported unaltered enzymatic
activity of this complex (Mortiboys et al., 2008; Grunewald et al.,
2010). Mitochondrial respiration is frequently measured to assess
how MRC enzymatic activities translate to global mitochondrial
function. Haylett et al. (2016) and Zanellati et al. (2015)
consistently observed increased basal mitochondrial respiration
in PRKN-PD fibroblasts but reported opposite outcomes in ATP-
linked respiration. In contrast to these findings, a previous study
described an overall decrease in all respiratory parameters of
PRKN-PD fibroblasts (Pacelli et al., 2011).
Mitochondrial membrane potential has also been widely
explored as a general marker of mitochondrial integrity in PRKN-
PD fibroblasts. While two authors were not able to demonstrate
alterations in this parameter (Grunewald et al., 2010; Haylett
et al., 2016), others reported decreased MMP (Zanellati et al.,
2015; Koentjoro et al., 2017), especially when exposing cells to
mitochondrial-challenging conditions (Mortiboys et al., 2008;
Grunewald et al., 2010).
Many evidences point to the involvement of PRKN in the
entire process of mitochondrial dynamics, including organelle
biogenesis, fusion/fission, and mitochondrial clearance via
mitophagy (Lim et al., 2012). In this context, mitochondrial
network morphology has been of interest in PRKN-PD fibroblasts
studies but with controversial results (Mortiboys et al., 2008;
Grunewald et al., 2010; Pacelli et al., 2011; van der Merwe et al.,
2014; Zanellati et al., 2015; Haylett et al., 2016). Although some
studies seem to agree that mitochondrial length is conserved
in these cells (Mortiboys et al., 2008; van der Merwe et al.,
2014; Haylett et al., 2016), others have observed a fragmented
mitochondrial network (Pacelli et al., 2011; Zanellati et al.,
2015). While most of studies did not show significant alterations
in mitochondrial branching (Grunewald et al., 2010; van der
Merwe et al., 2014; Zanellati et al., 2015), Haylett et al. (2016)
observed decreased levels and Mortiboys et al. (2008) reported
increased rates. In line with this, mitochondrial content has
been assessed in several works but only Grunewald et al. (2010)
reported a significant increase in this feature in PRKN-PD
fibroblasts whereas others have observed conserved (Mortiboys
et al., 2008; van der Merwe et al., 2014) or decreased levels
(Pacelli et al., 2011).
As previously discussed, oxidative stress is a hallmark of
mitochondrial dysfunction that has often been related with
neurodegeneration, specifically in PD (Guzman et al., 2010;
Surmeier et al., 2011; Poewe et al., 2017). In accordance, previous
authors demonstrated increased protein and lipid oxidation in
small cohorts (Grunewald et al., 2010; Pacelli et al., 2011).
Surprisingly, to our knowledge, studies assessing mitophagy
or autophagy in PRKN-PD fibroblasts are scarce. Only recently,
Koentjoro et al. (2017) elegantly demonstrated that a PRKN-
PD patient fibroblast cell line failed in initiating mitophagy
upon induction of mitochondrial depolarization. Interestingly,
they also examined an unusual homozygous PRKN mutation
carrier who did not develop clinical PD by her eight decade and
found preserved mitochondrial function due to the induction
of a PINK1/Parkin-independent mitophagy mediated by Nix,
which is a selective autophagic receptor located on the OMM
(Koentjoro et al., 2017).
Other studies in PRKN-PD fibroblasts have reported
alterations in alternative important cell processes which
represent promising targets of disease pathogenesis to be
further explored. For instance the regulation of endoplasmic
reticulum-to-mitochondrial contacts by Parkin via Mfn-2 (Basso
et al., 2018). Also, Pacelli et al. (2019) reported altered severe
damping of the bioenergetic oscillatory patterns associated to
circadian rhythms and molecular clockworks in fibroblasts from
PRKN-PD patients that may conditioning mitochondrial quality
control and mitophagy. One study performing a whole-genome
expression analysis by RNA-sequencing found that different
PRKN mutations were associated with a large number of
gene expression changes at the transcriptome level (González-
Casacuberta et al., 2018). Specifically, authors reported the
upregulation of 1C-dependent anabolic biosynthetic pathways,
which has been related with the activation of the mitochondrial
integrated stress response (ISRmt) in front of mitochondrial
dysfunction (Bao et al., 2016; Celardo et al., 2017; Suomalainen
and Battersby, 2017). Additional studies in PRKN-PD fibroblasts
have reported alterations in the protein expression and lipidome
profiles (Lippolis et al., 2015; Lobasso et al., 2017) as well as
cytoskeleton alterations such as microtubule destabilization
(Cartelli et al., 2012; Vergara et al., 2015).
The characterization of fibroblasts of PD patients point out
disrupted pathways to be targeted and therapeutic platforms, but
some concerns and controversies arise. The low reproducibility
of mitochondrial function analysis presented in most studies
performed up to date could be attributed to the small sample sizes
tested. Also differences in methodological approaches, protocols
and experimental conditions (e.g., site of skin biopsy, passage
number of cells, etc.) may partially account for the large variation
obtained. For instance, the use of different high-resolution
respirometry approaches in which oxygen consumption is
measured from seeding fibroblasts or from cells in suspension.
Similarly, assessing MRC enzymatic activities in intact cells or
in mitochondrial enriched fractions may contribute to outcome
disparities. Moreover, all the studies were performed in glycolytic
conditions that may partially unveil mitochondrial deficits and
contribute to controversy (Mortiboys et al., 2008; Grunewald
et al., 2010; Pacelli et al., 2011; van der Merwe et al., 2014;
Zanellati et al., 2015; Haylett et al., 2016). In this sense, the
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use of alternative sources of energy, as galactose, serves for two
purposes: to force and challenge oxidative metabolism (usage
widely extended for the diagnosis of mitochondrial disorders)
and mimic neuronal metabolism (mainly based in OXPHOS
function). Novel studies focused in exploring mitochondrial
or autophagic function in galactose may be useful to unveil
pathogenic mechanisms of disease.
In summary, the particular area of research focused on the
study of mitochondrial function in PRKN-PD fibroblasts has
proved to be contentious, with several groups either describing
similar defects or no apparent abnormalities. It would be of great
importance that researchers join efforts on homogenization of
protocols and analyzing a more significant number of PRKN-
PD patient-derived cells in order to unveil if mitochondrial
and autophagic dysfunction is a crucial event in PRKN-
PD pathogenesis.
DISEASE MODIFYING THERAPIES
Since the disseverment of PD, different therapeutic options have
been developed to ameliorate the symptoms of PD. The first
one to be developed was levodopa, in 1960, a precursor that
is transformed to DA in the brain, supplying the amount of
DA that degenerated neurons are not able to produce. Other
medications include DA agonists and monoamine oxidase-B
(MAO-B) or Catechol-O-methyltransferase inhibitors (COMT)
inhibitors, selegiline, and rasagiline, that decrease the activity
of MAO-B, enzyme responsible of degrading DA. There are
also other options to severe cases who do not respond to DA
based on the use of apomorphine and duodopa administered
by pumps, surgical interventions or deep brain stimulation
(Rizek et al., 2016).
However, these treatments are supportive, only control the
symptoms of the disease, the neurodegeneration is not stopped or
reversed, consequently, there are no curative treatments for PD.
To unveil the pathophysiology of the diseases and develop new
therapeutic strategies to reduce the impact of PD and find a cure
is essential to develop novel models of disease.
The experimental models herein discussed hold potential for
the development of PD modifying therapies. The complementary
assay of any potential candidate in different experimental models
confers strength to the potential therapeutic efficacy before
translation into the clinical settings. Patient-derived cell models
offer usefulness either as platforms for testing novel therapeutic
approaches or for prompting the discovery of novel targets from
disrupted pathways reported in these models.
The use of these experimental models in PD has permitted
the discovery of different therapeutic candidates, with different
degree of evidence on their potential therapeutic activity and
security concerns. This is the case of FGF20, echinacoside,
rosmarinic acid or autophagic modulators, as Threalose or Torin
1, among many others, targeting different disrupted cell pathways
in disease (Liang et al., 2019; Lv et al., 2019; Wang et al., 2019).
Depending on the subtype of PD, specific treatments have been
proposed. This is the case of LRRK2-PD carriers, where the
use of LRRK2 inhibitors has been proposed. They are currently
being tested in clinical I trials. Unfortunately, their systemic
action may unveil secondary effects, somehow bypassed by the
targeting of specific neural effectors (as PAK6 or Rab GTPases)
to modulate neural disrupted protein and organelle trafficking
in PD (Kiral et al., 2018). Similarly, for PRKN-patients, selective
mitochondrial drugs have been proposed. Experimental data
supports the use of fusion or fission inhibitors (as MDIVI-1),
that still rank in experimental settings (Manczak et al., 2019).
Antioxidant and mitochondrial principles (as coenzyme Q, that
failed in a phase III assay) and peroxisome proliferator-activated
receptor-γ agonists that reduces proinflammatory cytokines and
modulate mitochondrial biogenesis (as Pioglitazone) were also
tested in clinical trials, but failed to demonstrate further efficacy.
Apart from symptomatic treatments (such as levodopa
or surgical interventions), disease modification through
neuroprotection remains as the main milestone in PD research.
Neuroprotection tested by pramipexole (CALM-PD), ropinirole
(REAL-PD), and pramipexol (PROUD-PD) failed to establish
disease modification (Bartus et al., 2013; Obeso et al., 2017).
In this sense, calcium channel blockers aimed to prevent
calcium influx on nigral neurons are being tested (isradipine
is being evaluated in phase I and II clinical trials), together
with compounds able to increase urate antioxidant protection
(inosine is undergoing phase II studies) (Obeso et al., 2017).
Additionally, aiming to support neuroprotection through
the enhancement of neuronal viability, trophic factors are also
being evaluated in PD, showing moderate or null therapeutic
success. Of them, glial family ligands as glial derived neurotrophic
factor (GDNF) and neurturin in preclinical studies demonstrated
strong neuroprotection in multiple animal models. However,
multiple clinical trials, including 2 phase II trials, failed to
demonstrate their efficacy or showed significant side effects
(Kordower et al., 2000; Obeso et al., 2017).
Alpha-synuclein has become lately the major target for
PD therapeutics. Initial preclinical efforts concentrated on
synuclein-lowering treatments such as siRNAs directed against
alpha-synuclein, that resulted toxic in animals. Novel attempts
focused to disaggregate aggregated synuclein, facilitate its
clearance by augmenting autophagy pathways, or using
antibodies to prevent its propagation from the periphery
to the brain and once in the brain across the neural axis.
Vaccines against alpha-synuclein as both active and passive
immunization approaches have been attempted. Active
immunotherapy attempts to stimulate the immune system
against specific antigens (Bergström et al., 2016). Passive
immunotherapy uses monoclonal antibodies against alpha-
synuclein molecule. Initial phase 1 safety trials are currently
underway and show promising results in terms of safety and
tolerability profiles. The enhancement of glucocerebrosidase
(GBA) lysosomal activity to reduce alpha-synuclein levels is also
being tested through small molecule chaperones in clinical trials
(McNeill et al., 2014).
Probably the next coming years will open future perspectives
for the development of new supportive and curative therapies in
PD, where personalized medicine, mainly based on genetic and
molecular counseling, will help to direct specific PD patients to a
wide panoply of therapies.
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The development of novel therapeutic options will depend
of the efficacy of candidate compounds previously tested in
preclinical settings and experimental models of disease, as the
herein described, and the target of disrupted pathways, as the
herein explained.
CONCLUSION
Parkinson’s disease encompasses a wide panoply of genetic and
molecular etiologies leading to common clinical manifestations.
Different schools of thought differ in considering either
mitochondria or protein deposition-cascade as the triggers of
PD, but all they convey that PD pathogenesis is associated to
the deregulation of both mitochondrial and autophagic clearance
pathways, supporting its role in the disease. Mitochondrial
dysfunction and their turnover through autophagy directly
targets some types of PD (as those carrying mitochondrial or
autophagic mutations) but also stand at the base of the rest
of PD by providing the overdose of energy needed to support
alternative deregulated pathways while maintaining oxidative
stress levels within control ranges. Thus, proper mitochondrial
and autophagic function protects against PD and exhaustion of
mitochondrial and autophagy contributes to PD development,
independently of the genetic base. These molecular alterations
have been consistently reported in skin-derived fibroblasts from
PD patients carrying mutations in LRRK2 and PRKN genes.
These findings demonstrate the presence of molecular damage
characteristic of the PD target tissue beyond the CNS and the
usefulness of these patient-derived cells to model PD, models
that can be metabolically upgraded to resemble neuron behavior
and challenge mitochondrial and autophagic function by the
use of galactose.
Current research gaps in PD research stand for the
development of novel therapeutic candidates aimed to promote
healthy brain aging and avoid or even cure PD, probably
based in personalized-medicine guided by genetic and molecular
counseling. New generation sequencing will increase the number
of genes responsible of familial PD and the number of
genetic risk factors accounting for sporadic PD, thus unveiling
molecular imbalances underlying PD. Novel compounds against
these targets will be discovered in experimental settings and
disease models to set the path for further clinical trial testing.
Complementary models of disease will be needed to dissect
the disrupted pathways in PD and design specific therapeutic
targets, but the use of patient-derived cells such as fibroblasts is
gaining in strength because they constitute platforms to model
disease etiopathogenesis and try new therapeutic approaches in
the genetic and epigenetic background of the patient.
New challenges and potential developments in the field of
PD entail the validation of these novel therapeutic candidates
focused on modifying the course of PD through, among others,
promoting mitochondrial and autophagic performance.
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